What does PD-L1 positive or negative mean?

被引:253
|
作者
Ribas, Antoni [1 ,2 ]
Hu-Lieskovan, Siwen [1 ,2 ]
机构
[1] Univ Calif Los Angeles, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, JCCC, Los Angeles, CA 90095 USA
来源
JOURNAL OF EXPERIMENTAL MEDICINE | 2016年 / 213卷 / 13期
基金
美国国家卫生研究院;
关键词
CELL LUNG-CANCER; ADAPTIVE IMMUNE RESISTANCE; ADVANCED MELANOMA; UNTREATED MELANOMA; CLINICAL ACTIVITY; HODGKIN LYMPHOMA; OPEN-LABEL; EXPRESSION; BLOCKADE; NIVOLUMAB;
D O I
10.1084/jem.20161462
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Expression of the programmed death-1 (PD-1) ligand 1 (PD-L1) is used to select patients and analyze responses to anti-PD-1/L1 antibodies. The expression of PD-L1 is regulated in different ways, which leads to a different significance of its presence or absence. PD-L1 positivity may be a result of genetic events leading to constitutive PD-L1 expression on cancer cells or inducible PD-L1 expression on cancer cells and noncancer cells in response to a T cell infiltrate. A tumor may be PD-L1 negative because it has no T cell infiltrate, which may be reversed with an immune response. Finally, a tumor that is unable to express PD-L1 because of a genetic event will always be negative for PD-L1 on cancer cells.
引用
下载
收藏
页码:2835 / 2840
页数:6
相关论文
共 50 条
  • [1] A comparative study of PD-L1 diagnostic assays and the classification of patients as PD-L1 positive and PD-L1 negative
    Ratcliffe, Marianne J.
    Sharpe, Alan
    Midha, Anita
    Barker, Craig
    Scorer, Paul
    Walker, Jill
    CANCER RESEARCH, 2016, 76
  • [2] PD-1/PD-L1 blockade in paediatric cancers: What does the future hold?
    Moreno-Vicente, Julia
    Beers, Stephen A.
    Gray, Juliet C.
    CANCER LETTERS, 2019, 457 : 74 - 85
  • [3] Determination of PD-L1 positive CETCs as a biomarker for PD-1/PD-L1 treatment monitoring
    Pizon, M.
    Schott, D.
    Pachmann, U.
    Pachmann, K.
    ONCOLOGY RESEARCH AND TREATMENT, 2017, 40 : 89 - 89
  • [4] Identifying immune infiltration pattern of PD-L1 positive and negative lung adenocarcinoma
    Heidel, C.
    Jokic, M.
    Faehnrich, A.
    Kuempers, C.
    Vogel, W.
    Vlasic, I.
    Kirfel, J.
    Busch, H.
    Perner, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 110 - 111
  • [5] Macrophages are important source of PD-L1 and PD-L1 expressing in macrophages affect the prognosis of NSCLC patients with tumor PD-L1 negative
    Liu, Y.
    Cao, L.
    Che, X.
    Qiu, X.
    Li, Z.
    Yang, B.
    Wang, S.
    Qu, X.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2019, 49 : 531 - 532
  • [6] The efficacy of PD-L1 blockade on PD-L1 negative medulloblastoma is dependent on timing and the tumor microenvironment
    Allen, Frederick
    Dorand, Rodney Dixon
    Rauhe, Peter
    Petrosiute, Agne
    Huang, Alex Y.
    JOURNAL OF IMMUNOLOGY, 2018, 200 (01):
  • [7] What does radiomics do in PD-L1 blockade therapy of NSCLC patients?
    Cui, Ruichen
    Yang, Zhenyu
    Liu, Lunxu
    THORACIC CANCER, 2022, 13 (19) : 2669 - 2680
  • [8] Frequency of PD1-negative and PD-1-positive ILCs in breast cancer patients depending on PD-L1 status
    Alifanov, V. V.
    Buzenkova, A.
    Popova, N. O.
    Savelieva, O. E.
    Tashireva, L. A.
    Perelmuter, V. M.
    ANNALS OF ONCOLOGY, 2021, 32 : S858 - S858
  • [9] Beyond PD-L1: Unraveling the enigma of immunotherapy response in PD-L1 negative (<1%) NSCLC patients through quantification of PD-1/PD-L1 engagement in the tumor microenvironment
    Gumuzio, Juan
    Calleja, Veronique
    Miles, James
    Sancehz-Magraner, Lissete
    Aguirre, Fernando
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [10] Platelet PD-L1 suppresses anti-cancer immune cell activity in PD-L1 negative tumors
    Alexander B. Zaslavsky
    M. P. Adams
    X. Cao
    T. Maj
    J. E. Choi
    J. Stangl-Kremser
    S. Patel
    A. Putelo
    S. K. Lee
    S. Nallandhighal
    A. Kasputis
    A. Alva
    M. Lew
    A. Qin
    R. Mehra
    T. M. Morgan
    S. S. Salami
    Z. Reichert
    A. Udager
    W. Zou
    Ganesh S. Palapattu
    Scientific Reports, 10